Literature DB >> 9757936

Kinetics of procalcitonin in iatrogenic sepsis.

F M Brunkhorst, U Heinz, Z F Forycki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9757936     DOI： 10.1007/s001340050683

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

1.  Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection.

Authors:  O K Eberhard; M Haubitz; F M Brunkhorst; V Kliem; K M Koch; R Brunkhorst
Journal:  Arthritis Rheum       Date:  1997-07

2.  Procalcitonin as a marker for the early diagnosis of neonatal infection.

Authors:  D Gendrel; M Assicot; J Raymond; F Moulin; C Francoual; J Badoual; C Bohuon
Journal:  J Pediatr       Date:  1996-04       Impact factor: 4.406

3.  High serum procalcitonin concentrations in patients with sepsis and infection.

Authors:  M Assicot; D Gendrel; H Carsin; J Raymond; J Guilbaud; C Bohuon
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

4.  Procalcitonin increase after endotoxin injection in normal subjects.

Authors:  P Dandona; D Nix; M F Wilson; A Aljada; J Love; M Assicot; C Bohuon
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958
  4 in total
  49 in total

1.  Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome.

Authors:  R Arkader; E J Troster; M R Lopes; R R Júnior; J A Carcillo; C Leone; T S Okay
Journal:  Arch Dis Child       Date:  2005-12-02       Impact factor: 3.791

2.  Predictive value of procalcitonin for the diagnosis of bowel strangulation.

Authors:  B Papaziogas; G Anthimidis; I Koutelidakis; S Atmatzidis; K Atmatzidis
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

3.  Procalcitonin for antibiotic treatment in intensive care unit patients.

Authors:  Nathalie Layios; Bernard Lambermont
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

Review 4.  Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Authors:  Dubravka Kojic; Benedikt H Siegler; Florian Uhle; Christoph Lichtenstern; Peter P Nawroth; Markus A Weigand; Stefan Hofer; Thorsten Brenner
Journal:  World J Exp Med       Date:  2015-05-20

Review 5.  De-escalating Antibiotic Use in the Inpatient Setting: Strategies, Controversies, and Challenges.

Authors:  J Daniel Markley; Shaina Bernard; Gonzalo Bearman; Michael P Stevens
Journal:  Curr Infect Dis Rep       Date:  2017-04       Impact factor: 3.725

6.  Elevated procalcitonin as a diagnostic marker in meningococcal disease.

Authors:  G D Mills; H M Lala; M R Oehley; A B Craig; K Barratt; D Hood; C N Thornley; A Nesdale; N E Manikkam; P Reeve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

7.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children?

Authors:  Dilshad Ahmad Khan; Aisha Rahman; Farooq Ahmad Khan
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

9.  Diagnostic value of lipopolysaccharide-binding protein and procalcitonin for sepsis diagnosis in forensic pathology.

Authors:  Marc Augsburger; Katia Iglesias; Daniel Bardy; Patrice Mangin; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2012-10-13       Impact factor: 2.686

10.  The diagnostic and prognostic accuracy of five markers of serious bacterial infection in Malawian children with signs of severe infection.

Authors:  Enitan D Carrol; Limangeni A Mankhambo; Graham Jeffers; Deborah Parker; Malcolm Guiver; Paul Newland; Daniel L Banda; Elizabeth M Molyneux; Robert S Heyderman; Malcolm E Molyneux; C Anthony Hart
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.